A Phase I Study in Healthy Male and Healthy Female Subjects to Characterize the Safety, Tolerability, and Pharmacokinetics of Intravenous Infusion of MTP-131 (Bendavia) Using a Randomized, Double-Blind, Placebo-Controlled, Parallel Group Design.

Trial Profile

A Phase I Study in Healthy Male and Healthy Female Subjects to Characterize the Safety, Tolerability, and Pharmacokinetics of Intravenous Infusion of MTP-131 (Bendavia) Using a Randomized, Double-Blind, Placebo-Controlled, Parallel Group Design.

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Jun 2015

At a glance

  • Drugs Elamipretide (Primary)
  • Indications Myocardial reperfusion injury
  • Focus Adverse reactions
  • Sponsors Stealth Peptides
  • Most Recent Events

    • 13 Sep 2010 Status changed from recruiting to completed, based on a Stealth Peptides media release.
    • 13 Sep 2010 Results reported in a Stealth Peptides media release.
    • 15 Jun 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top